| Literature DB >> 28496483 |
Mahboobeh Talebi Mehrdar1, Rasool Madani2, Reza Hajihosseini1, Soheila Moradi Bidhendi3.
Abstract
The aim of this study is to investigate antibacterial effects of immunodominant proteins isolated from the venom of Naja Naja Oxiana snake against Staphylococcus aureus, Escherichia coli, Bacillus subtilis and Pseudomonas aeruginosa. The innate immune system is an important line of defense against bacterial diseases. Antibacterial peptides and proteins produced by snake venoms have recently attracted significant attention due to their relevance to bacterial diseases and the potential of being converted into new therapeutic agents. Identification of immunodominant proteins of the venom of Naja Naja Oxiana snake was performed by SDS-PAGE and western blot analysis. Identified proteins were isolated directly from preparative gel electrophoresis by Electro-elution. In the next step, antibacterial effects of immunodominant proteins were tested against several strains of clinical isolates, including S.aureus, B.subtilis (Gram-positive bacteria) P.aeruginosa and E.coli (Gram-negative bacteria) using broth microdilution and disc-diffusion assays. In order to compare the results of the disc-diffusion assay, antibacterial effects of several antibiotics (Gentamicin, Ampicillin, Penicillin, Amoxicillin and Ciprofloxacin) were also examined using the same conditions. Results showed that immunodominant proteins of (14, and 65kDa) with high immunogenicity were very effective in inhibiting the growth of two Gram-positive bacteria (S.aureus, B.sub) that were tested. However, they were only moderately effective in inhibiting the growth of the two tested Gram-negative bacteria (P.aeruginosa and E.coli). However, immunodominant proteins of 22 kDa and 32kDa with high immunogenicity, showed slight effectiveness in inhibiting the growth of two; the Gram-positive and Gram-negative bacteria that were tested. To the best of our knowledge, these immunodominant proteins are novel antigens for potent antimicrobial effects against two gram-positive bacteria (S.aureus, B.subtilis ) and less antimicrobial effect against two gram-negative bacteria (E.coli, P.aeruginosa) that were prepared .Entities:
Keywords: Antibacterial effect; Electroelution; Immunodominant protein; Naja Naja
Year: 2017 PMID: 28496483 PMCID: PMC5423255
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Figure 1Separation of Naja Naja proteins venom by SDS-PAGE (15%) 1) Molecular weight markers. 2) crude venom (dilution 1:2).3) crude venom (dilution 1:4
Figure 2Western blot analysis on Naja Naja venom .1) Molecular weight markers and crude venom from Naja Naja snake after transfered onto nitrocellulose membrane, by SDS-PAGE (15%). Coomassie brilliant blue R-250 stain 2) Immunological reactivity of antibody and crude venom from Naja Naja snake
Antibacterial activity of immunodominant proteins crude isolated of N.naja oxiana venom tested by disc-diffusion and compared to some standard antibiotics. Each number is presented as mean + SD of inhibition zone in mm,(n = 4
|
|
|
|
|
|
|---|---|---|---|---|
| Immunodominant protein 0f 14 kDa | 10/83 ± 0/28 | 10/66 ± 0/28 | 16/5 ± 0/5 | 13/16 ± 0/28 |
| Immunoominant protein of 22 kDa | 6.7 | 7/1 ± 0/36 | 7/1 ± 0/36 | 10/13 ± 0/32 |
| Immunodominant protein of 32 kDa | 6/93 ± 0/11 | 7/6 ± 0/52 | 8/1 ± 0/36 | 12/73 ± 0/25 |
| Immunodominant protein of 65 kDa | 7/6 ± 0/52 | 7/43 ± 0/40 | 15/76 ± 0/25 | 14/5 ± 0/5 |
| Ampicillin | 0.0 | 8/26 ± 0/55 | 19/26 ± 0/64 | 24/13 ± 0/41 |
| Gentamicin | 18 ± 0/2 | 19/04 ± 0/16 | 35/88 ± 0/34 | 16/13 ± 0/20 |
| Penicillin | 0.0 | 0.0 | 9/13 ± 0/32 | 0.0 |
| Ciprofloxacin | 0.0 | 35/66 ± 0/57 | 30/88 ± 0/34 | 24/02 ± 0/13 |
| Amoxiclav | 0.0 | 14/27 ± 0/26 | 18/46 ± /57 | 20 ± 0/8 |
Antibacterial activities of isolated immunodominant proteins of Naja Naja Oxiana
|
|
|
|
|---|---|---|
|
| ||
|
| Immunodominant protein 0f 14 kDa | 75 |
| Immunoominant protein of 22 kDa |
| |
| Immunodominant protein of 32 kDa | >175 | |
| Immunodominant protein of 65 kDa | ≥125 | |
| Ampicillin | 120 | |
| Gentamicin | <10 | |
| Penicillin | >200 | |
| Ciprofloxacin | <5 | |
| Amoxiclav | 25 | |
|
| Immunodominant protein 0f 14 kDa | 75 |
| Immunoominant protein of 22 kDa |
| |
| Immunodominant protein of 32 kDa | >175 | |
| Immunodominant protein of 65 kDa | ≥125 | |
| Ampicillin | >200 | |
| Gentamicin | <10 | |
| Penicillin | >200 | |
| Ciprofloxacin | >200 | |
| Amoxiclav | >200 | |
|
| Immunodominant protein 0f 14 kDa | 37.5 |
| Immunoominant protein of 22 kDa |
| |
| Immunodominant protein of 32 kDa | 87 | |
| Immunodominant protein of 65 kDa | 26 | |
| Ampicillin | 25 | |
| Gentamicin | 10 | |
| Penicillin | >200 | |
| Ciprofloxacin | <5 | |
| Amoxiclav | 10 | |
|
| Immunodominant protein 0f 14kDa | 37.5 |
| Immunoominant protein of 22 kDa |
| |
| Immunodominant protein of 32kDa | >175 | |
| Immunodominant protein of 65 kDa | 31 | |
| Ampicillin | 25 | |
| Gentamicin | 10 | |
| Penicillin | 120 | |
| Ciprofloxacin | <5 | |
| Amoxiclav | 25 |